News | July 29, 2025
Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Subscribe To Our Newsletter & Stay Updated
